Clinical Resources: Buprenorphine in Borderline Personality Disorder
Primary Care Materials
This page hosts practical resources for clinicians and patients exploring the potential role of buprenorphine in Borderline Personality Disorder (BPD), particularly in cases marked by severe interpersonal dysregulation, affective instability, and self-injurious behavior.
These materials are educational and mechanism-focused. They are not formal treatment guidelines and do not replace clinical judgment.
Primary Care Guide
These guides are written for primary care clinicians and other prescribers who are comfortable with buprenorphine in other contexts (e.g., pain or OUD) but have not considered its potential role in affective and interpersonal dysregulation.
Status
These guides are shared to invite thoughtful feedback from clinicians, researchers, and people with lived experience. They are working documents and will be revised as new evidence and clinical insight develops.
Changelog
Document version history
PCP Guide
| Date | Version | Changes |
|---|---|---|
| March 25, 2026 | v0.15 | Added authorship and provenance disclosure to opening section. |
| April 1, 2026 | v0.16 | Added citations throughout. New supporting sentences added for Prossin et al. (2010) on PET neuroimaging evidence for μ-opioid receptor availability in BPD, New and Stanley (2010) on the endogenous opioid deficit synthesis, Gescher et al. (2024) on trauma-linked OPRK1 methylation changes, and Khalili et al. (2019) in the bipolar spectrum section. |
| April 4, 2026 | v0.17 | Refined naltrexone contraindication language throughout: replaced "absolutely contraindicated" with "contraindicated in primary care settings," scoped the contraindication explicitly to milligram-dosed formulations, and added a carve-out acknowledging experimental concurrent ultra-low-dose naltrexone (ULDN, <10 mcg) use in pain management literature while noting it falls outside routine primary care protocols. Updated PDMP section to clarify that only concurrent milligram-dosed naltrexone is contraindicated. Added citation for Toljan and Vrooman (2018) on LDN to support the ULDN concurrent use statement. Added new Section 6.3 describing the Norelli et al. (2013) case series on buprenorphine for treatment-refractory NSSI, with discussion of aggregate outcome data, prior naltrexone failure across cases, and tolerability considerations. Added Norelli et al. (2013) to Section 13 evidence summary. Added Bershad et al. (2015) as a new evidence thread in Section 13 on buprenorphine's attenuation of psychosocial stress responses in a controlled human experimental paradigm. |
| April 8, 2026 | v0.18 | Added citations throughout. In Section 1, refined prevalence language to distinguish point prevalence from lifetime prevalence estimates and disaggregated clinical setting prevalence figures by care context (primary care, psychiatric outpatient, psychiatric inpatient); added citations for Lenzenweger et al. (2007), Grant et al. (2008), Gross et al. (2002), and Lieb et al. (2004). Added Riihimäki et al. (2014) on BPD prevalence among primary care depressive patients. Added Paris and Zweig-Frank (2001), Temes et al. (2019), and Wu et al. (2022) to support suicide mortality figures. Added Bender et al. (2001) on healthcare utilization. Added Sansone and Sansone (2012) on chronic pain comorbidity. Added Eisenberger et al. (2003) on the neural overlap of social and physical pain. Added Pitman et al. (1990) on naloxone-reversible stress-induced analgesia in PTSD. Added Lutz and Kieffer (2013) on opioid receptor roles in mood disorders. Added Lutfy and Cowan (2004) on buprenorphine pharmacology. Added Simeon and Knutelska (2005) on naltrexone in depersonalization disorder. Added Pergolizzi et al. (2010) on buprenorphine pharmacological profile. Added Stoffers-Winterling et al. (2022) on pharmacological interventions for BPD. Added Strain et al. (2004) on naloxone sublingual bioavailability. Added Posner et al. (2011) on the C-SSRS. Added McEwen (2017) on neuroplastic effects of chronic stress. Added ACOG Committee Opinion (2017) on opioid use in pregnancy. Added Linehan (1993) on the biosocial theory of BPD. Added Roth et al. (1996) on naltrexone for repetitive self-injurious behavior. Added Younger et al. (2014) on low-dose naltrexone mechanism. Added FDA Suboxone prescribing information and FDA benzodiazepine drug class boxed warning (2020) as regulatory references. |
Quick Reference
| Date | Version | Changes |
|---|---|---|
| March 25, 2026 | v0.2 | Added authorship and provenance disclosure to footer. |
Guidance Notes
A recently identified case series (Norelli et al.) reported clinical use of buprenorphine/naltrexone combination products at doses of 2/0.5 mg and 1/0.25 mg in this context — naltrexone, not naloxone, which has negligible oral bioavailability and is used in standard sublingual formulations precisely to deter injection. This is the first such report known to this site, and the pharmacodynamic implications of the naltrexone component at these doses are not yet well understood here. The PCP guide will be updated once that is better characterized. In the meantime, this is noted for clinicians who may encounter or consider combination formulations.
If you have relevant clinical experience or insight into this combination, please get in touch.
Contact
For questions, feedback, or discussion:
contact@bpd.fyi